Clinical trials Brief October 19, 2026, 10:03 AM ET

R-Pharm registers Phase 3 study of Goflikicept in pediatric FMF

The study plans to enroll 18 participants and plans to begin in December 2026, with primary completion projected for May 2029. It aims to evaluate the pharmacokinetics, efficacy, and safety of goflikicept in children and adolescents with colchicine-resistant or colchicine-intolerant familial Mediterranean fever.

Primary source

ClinicalTrials.gov registry record, October 19, 2026

Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever

Read the source: Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation